Shaanxi Kanghui Pharmaceutical Co., Ltd.

SHSE:603139 Stock Report

Market Cap: CN¥1.6b

Shaanxi Kanghui Pharmaceutical Valuation

Is 603139 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603139 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 603139's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 603139's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603139?

Key metric: As 603139 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 603139. This is calculated by dividing 603139's market cap by their current revenue.
What is 603139's PS Ratio?
PS Ratio2.6x
SalesCN¥605.28m
Market CapCN¥1.56b

Price to Sales Ratio vs Peers

How does 603139's PS Ratio compare to its peers?

The above table shows the PS ratio for 603139 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.3x
600381 Qinghai Spring Medicinal Resources Technology
6.9xn/aCN¥1.7b
002898 Sailong Pharmaceutical GroupLtd
6.4xn/aCN¥1.9b
600272 Shanghai Kai Kai Industry
2.7xn/aCN¥2.2b
002370 Zhejiang Yatai Pharmaceutical
5.1xn/aCN¥2.2b
603139 Shaanxi Kanghui Pharmaceutical
2.6xn/aCN¥1.6b

Price-To-Sales vs Peers: 603139 is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (5.3x).

Price to Sales Ratio vs Industry

How does 603139's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
600664 Harbin Pharmaceutical Group
0.6xn/aUS$1.28b
000411 Zhejiang Int'l GroupLtd
0.2xn/aUS$777.77m
000153 Anhui Fengyuan Pharmaceutical
0.7xn/aUS$410.69m
600781 FUREN Group PharmaceuticalLtd
0.3xn/aUS$66.91m
603139 2.6xIndustry Avg. 3.5xNo. of Companies35PS02.85.68.411.214+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 603139 is good value based on its Price-To-Sales Ratio (2.6x) compared to the CN Pharmaceuticals industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is 603139's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603139 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 603139's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.31

7D

-1.4%

1Y

-24.4%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.59

7D

-2.4%

1Y

12.8%

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.51

7D

2.2%

1Y

7.6%